Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.47 |
| ▸ | NAMPT | P43490 | 4/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070463 | 0.90 | IMPDH2 (0.54) | MAOBROCK2NAMPTRORCMAPT | |
| SCHEMBL6070912 | 0.89 | MAPK1 (0.51) | MAOBROCK2RORC | |
| SCHEMBL6070792 | 0.87 | ROCK2 (0.49) | MAOBROCK2MAPTPOLB | |
| SCHEMBL6070867 | 0.84 | ROCK2 (0.48) | ROCK2MAPTPOLBNPC1 | |
| SCHEMBL6071299 | 0.82 | ROCK2 (0.49) | MAOBROCK2 | |
| SCHEMBL5413102 | 0.81 | MAOB (0.71) | MAOBROCK2NAMPTL3MBTL1NPC1 | |
| SCHEMBL6071307 | 0.81 | MAOB (0.41) | MAOBL3MBTL1NPC1RAB9A | |
| SCHEMBL6071038 | 0.81 | MAOB (0.39) | MAOBROCK2RORCMAPTSMN1; SMN2 | |
| SCHEMBL6071398 | 0.80 | MAPT (0.53) | MAPTTP53POLBRXFP1NPC1 | |
| SCHEMBL6071553 | 0.80 | ITK (0.51) | MAPTTP53SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264493-A1 | Tetracyclic pyrazole derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K1, MAP3K19, MAP3K20 | MAOB 3302/4885ROCK2 698/4885NAMPT 1336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.